In This Issue:
Proposed merger of private labs under scrutiny
The Competition and Consumer Commission of Singapore has just sought public feedback on the two-year commitments proposed by Pathology Asia Holdings to address concerns that the proposed merger of two of its private clinical laboratories will substantially reduce competition in the Singapore market for in vitro diagnostic tests.
Under Singapore competition law, mergers that substantially lessen competition in Singapore are prohibited. The Innovative-Quest merger has therefore been under strict scrutiny for its potentially detrimental impact on competition in the Singapore healthcare market on healthcare costs and health insurance premiums.
Standardised packaging and enlarged graphic health warnings for tobacco products from 1 July 2020
The Ministry of Health has announced the implementation of the Standardized Packaging Measure (“SP Measure”), which requires all tobacco products in Singapore to follow a standardised packaging with enlarged graphic health warnings.
To effect the SP Measure, the MOH will be introducing new subsidiary legislation, one of which is the Tobacco (Control of Advertisements and Sale) (Appearance, Packaging and Labelling) Regulations 2019, which were published on 1 July 2019 and will come into operation on 1 July 2020.
"Organisers" redefined under the Singapore Association of Pharmaceutical Industries Code of Conduct
The Singapore Association of Pharmaceutical Industries Code of Conduct (the "SAPI Code") has been amended to provide clearer guidelines on the definition of the word “Organisers” in article 7.4.2 (Third Party Educational Events).
The amended guidelines pertain to article 7.2.4 ii on the sponsorship of healthcare professionals attending third party educational events.